go-v.orgdoi

Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

Yongming Kang, Pan Song, Kun Fang, Bo Yang, Luchen Yang, Jing Zhou, Linchuan Wang, Qiang G Dong · Journal of Cancer · 2020

  • DOI 10.7150/jca.40428
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2020

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2020

Abstract

Objective: To evaluate the prostate cancer-specific survival (PCSS) of low T stages or low prostatespecific antigens (PSA) levels in men with high-grade prostate cancer.

Materials and Methods:Patients with non-metastatic prostate cancer (T1-4N0M0) and Gleason score 8-10 in the Surveillance, Epidemiology, and End Results database from 2004-2010 were identified.These men were stratified by T stages (T1, T2, T3a, T3b-4) and PSA levels (<4.0 ng/ml, 4.0-10.0ng/ml, 10.1-20.0ng/ml, >20.0 ng/ml).Propensity-score matching (PSM) was conducted to balance the covariates.Kaplan-Meier analysis and multivariable Cox regressions were performed to analyze the PCSS in different T stage or PSA levels groups.Results: A total of 33231 patients aging 69(62~76) years were identified.The overall cohort results showed that the PCSS of T1 group was significantly worse than that of T2 and T3a groups [T2 HR: 0.62(0.57~0.67);T3 HR: 0.70(0.63~0.77)].There were no significant difference between T2 and T3a groups [T2 HR: 0.98 (0.91~1.05)].The PSA <4.0 ng/ml group had significantly worse PCSS than PSA 4.0-10.0ng/ml [PSA 4.0-10.0ng/ml HR: 0.77(0.68~0.88)].PSM methods were implemented in the comparison of T1 vs T2, T1 vs T3a, T2 vs T3a. and PSA< 4.0 ng/ml vs PSA 4.0-10.0ng/ml, The results in these matched cohorts showed that T1 group was associated with significantly worse PCSS than T2 group [T1 HR: 1.31(1.20~1.44)]and T3a group [T1 HR: 1.33(1.16~1.52)].There were no significant differences between T2 and T3a groups [T3a HR: 1.14(0.99~1.32)].The PCSS of patients with PSA< 4.0 ng/ml was significantly worse that these with PSA 4.0-10.0ng/ml in the matched cohort [PSA< 4.0 ng/ml HR: 1.3(1.08~1.56)].Conclusions: For patients with high-grade PCa, the PCSS of patients seems to be worse in the T1 stage than those in T2 and T3a stages.Patients with PSA <4.0 ng/ml appears to have poorer prognosis than those with PSA 4.0-10.0ng/ml.

Open the resolved locator · 10.7150/jca.40428

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:24 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v11p6484.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.